The concern of generic competition has long loomed around copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the future of connected drug investments. While initial times saw significant gains, the intellectual property lapse has created the door for website discounted substitutes, possibly lowering profitability and presenting a